NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy: NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy